Sugi Predict

Sugi Predict / Compounds / SCHEMBL653567

SCHEMBL653567

SCHEMBL653567

O=[N+]([O-])c1cccnc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 1/20 0.56
▸ POLB P06746 1/20 0.55
▸ ALDH1A1 P00352 6/20 0.50
▸ CYP1A2 P05177 2/20 0.50
▸ CYP2C9 P11712 2/20 0.50
▸ NCOA1 Q15788 1/20 0.50
▸ NCOA3 Q9Y6Q9 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ MEN1 O00255 6/20 0.49
▸ KMT2A Q03164 6/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ LMNA P02545 3/20 0.46
▸ PAX8 Q06710 1/20 0.46
▸ MAPT P10636 4/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ CTSB P07858 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ IDO1 P14902 1/20 0.46
▸ TDO2 P48775 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30231123 1.00 PDE10A (0.56) PDE10APOLBALDH1A1CYP1A2CYP2C9
Cyanide SCHEMBL27930555 0.94 PDE10A (0.51) PDE10APOLBALDH1A1CYP1A2CYP2C9
Formic Acid SCHEMBL28247378 0.91 PDE10A (0.49) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL30731266 0.79 ALDH1A1 (0.54) PDE10APOLBALDH1A1MEN1KMT2A
SCHEMBL29940575 0.78 PDE10A (0.60) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL6512953 0.78 PDE10A (0.60) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL3150556 0.78 ALDH1A1 (0.75) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL294121 0.77 PDE10A (0.58) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL29579675 0.77 PDE10A (0.58) PDE10APOLBALDH1A1CYP1A2CYP2C9
SCHEMBL244559 0.77 HSP90AA1 (0.59) PDE10APOLBALDH1A1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115991873-A Low-dielectric fluorinated aromatic polyimide film and preparation method thereof 慧创(东莞)材料技术有限责任公司 2023-04-21 — — CN claimed
CN-108498520-A A kind of pharmaceutical composition and preparation method thereof for treating periodontitis 戚建民 2018-09-07 — — CN claimed
CN-103102301-B Preparation method of substituted pyridine-2-sulfonium salt UNIV NINGBO 2015-01-21 — — CN claimed
CN-103102301-A Preparation method of substituted pyridine-2-sulfonium salt UNIV NINGBO 2013-05-15 — — CN claimed
CN-115650982-B Compounds for imaging TAU protein aggregates AC免疫有限公司 2026-05-19 — — CN disclosed
US-20250368667-A1 USP1 INHIBITOR SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD (CN) 2025-12-04 — — US disclosed
EP-4582427-A1 USP1 INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2025-07-09 — — EP disclosed
US-20250145597-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-05-08 — — US disclosed
CN-119923385-A Inhibitors of RNA helicase DHX9 and uses thereof 埃克森特治疗公司 2025-05-02 — — CN disclosed
US-12233065-B2 Inhibitors of RNA helicase DHX9 and uses thereof ACCENT THERAPEUTICS, INC. (US) 2025-02-25 — — US disclosed
CN-119497713-A USP1 inhibitors 上海齐鲁制药研究中心有限公司 2025-02-21 — — CN disclosed
EP-3873900-B1 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES GILEAD SCIENCES INC (US) 2025-01-08 — — EP disclosed
EP-0673937-A1 BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES Eisai Co., Ltd. (JP) 1995-09-27 — — EP disclosed
CN-1082028-A 3-fluorine pyridine, its preparation method and the application in liquid crystal compound HOECHST AG (DE) 1994-02-16 — — CN disclosed
EP-0165753-B1 HERBICIDAL THIOPHENESULFONAMIDES AND PYRIDINESULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-12-11 — — EP disclosed
US-4784684-A Herbicidal pyridinesulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1988-11-15 — — US disclosed
US-4668279-A PLANT GROWTH REGULATORS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-05-26 — — US disclosed
EP-0165753-A2 Herbicidal thiophenesulfonamides and pyridinesulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-12-27 — — EP disclosed
EP-0040408-A1 Beta-lactam compounds and process for production thereof SANRAKU-OCEAN CO., LTD. (JP) 1981-11-25 — — EP disclosed
EP-0013145-A2 Substituted anilinopyridines, processes for their preparation and intermediates for use therein, compositions and herbicidal use thereof ICI AUSTRALIA LIMITED (AU) 1980-07-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12233065-B2 Inhibitors of RNA helicase DHX9 and uses thereof DHX29, DHX9, DDX39B PDE10A 3061/4885POLB 79/4885ALDH1A1 1705/4885
US-20250368667-A1 USP1 INHIBITOR USP1, USP2, USP28 PDE10A 3274/4885POLB 2139/4885ALDH1A1 644/4885
US-20250145597-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B PDE10A 2780/4885POLB 279/4885ALDH1A1 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.